Clinical trials: Percutaneous Coronary Intervention Patients
Periprocedural Myocardial Necrosis
Rosuvastatin in Preventing Myonecrosis in Elective Percutaneous Coronary Interventions (PCIs)
An increase in cardiac biomarkers has been shown to occur in 5% to 30% of patients after otherwise successful percutaneous coronary interventions (PCIs)(1) Apart from side-branch occlusion, intimal dissection and coronary spasm…
- Trial name
- ROMA (NCT01007279)
- Testing
- ROSUVASTATIN
- Where
- Italy
- Volunteers
- 160 people
- Sponsor
- University of Roma La Sapienza
Coronary Artery Disease
A Registry Trial of The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
This study is a prospective, multi-center single arm registry trial, planning to enroll 785 subjects. All subjects will receive clinical follow-up at 1 month, 6 month, 9 month and 1, 2, 3, 4, 5 year after index procedure.
- Trial name
- NCT04179045
- Testing
- The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
- Where
- 5 sites in China
- Volunteers
- 785 people
- Sponsor
- Shanghai Bio-heart Biological Technology Co., Ltd.
Coronary Artery Disease
PeRcutaneous cOronary Intervention of Native Coronary arTery Versus Venous Bypass Graft in Patients With Prior CABG
Multi-centre, randomised clinical trial with anticipated 17 European centres: in the Netherlands, Belgium, Germany and UK. Patients with a dysfunctional bypass graft with a clinical indication for revascularization will be…
- Trial name
- PROCTOR (NCT03805048)
- Testing
- Percutaneous coronary intervention
- Where
- 21 sites in Belgium, Germany and 3 more
- Volunteers
- 221 people
- Sponsor
- Amsterdam UMC, location VUmc
Myocardial Infarction
Diagnostic and Prognostic Utility of Pentraxin 3 in Patients With Acute STEMI Undergoing Primary PCI
A number of inflammatory markers have been recognized, among which the acute phase reactant C-reactive protein showed a positive correlation with the risk of coronary artery disease in both healthy individuals and those at high…
- Trial name
- NCT03476252
- Testing
- pentraxin 3
- Volunteers
- 100 people
- Sponsor
- Assiut University
ST Elevation Myocardial Infarction
Outcome of Primary PCI in STEMI Addict Patients
The goal of this study is to Identify the in-hospital outcome of primary PCI in treatment of STEMI in addict patients in comparison to non-addict patients.
- Trial name
- NCT04090216
- Testing
- Primary Percutaneous Coronary Intervention
- Volunteers
- 176 people
- Sponsor
- Assiut University
Coronary Artery Disease
Korean Multicenter Randomized Controlled Trial (RCT) of Pidogul for Patients With Coronary Stenting
The aim of the current study is to compare the antiplatelet efficacy and safety of clopidogrel napadisilate and clopidogrel bisulfate in Coronary Artery Disease (CAD) patients after coronary stent implantation.
- Trial name
- NCT01584791
- Testing
- clopidogrel napadisilate + aspirin, clopidogrel bisulfate + aspirin
- Where
- South Korea
- Volunteers
- 148 people
- Sponsor
- Seoul National University Hospital
Coronary Artery Disease
Prevention of Restenosis After Genous Stent Implantation Using a Paclitaxel Eluting Balloon in Coronary Arteries
Percutaneous coronary intervention with stent implantation is limited on the one hand by restenosis due to smooth muscle cell proliferation and on the other hand by stent thrombosis due to incomplete or not sufficient enough…
- Trial name
- NCT00732953
- Testing
- Genous stent implantation with paclitaxel-eluting balloon dilation, Genous stent implantation
- Where
- 3 sites in Germany
- Volunteers
- 120 people
- Sponsor
- University of Ulm
Myocardial Ischemia, Acute Coronary Syndrome
EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)
The purpose of this study is to see if early INTEGRILIN® (eptifibatide) therapy in patients with non-ST-segment elevation acute coronary syndrome (ACS) reduces the occurence of death, heart attack and urgent cardiac intervention…
- Trial name
- NCT00089895
- Testing
- Eptifibatide (Integrilin)
- Volunteers
- 9,406 people
- Sponsor
- Organon and Co
Critical Limb Ischemia
Impact of Critical Limb Ischemia on Long Term Cardiac Mortality in Diabetic Patients Undergoing Percutaneous Coronary Revascularization
Prospective cohort study of consecutive diabetic patients undergoing percutaneous coronary intervention (PCI) in whom development of critical limb ischemia was prospectively assessed by a dedicated diabetic foot clinic.
- Trial name
- NCT01676519
- Testing
- PCI
- Where
- Italy
- Volunteers
- 764 people
- Sponsor
- Ospedale San Donato
ST Elevation (STEMI) Myocardial Infarction
PICSO in Patients With STEMI Treated by Primary Percutaneous Coronary Intervention
A prospective multi-center study in which patients with an acute heart attack (in the left anterior descending artery) with ECG changes (ST segment elevation) receive angioplasty followed by stent placement and 90 minutes of…
- Trial name
- pRAMSES (NCT01493037)
- Testing
- PICSO (Pressure-controlled Intermittent Coronary Occlusion
- Where
- 2 sites in Netherlands
- Volunteers
- 30 people
- Sponsor
- Miracor Medical SA
Coronary Arterial Disease (CAD)
The Switching Antiplatelet-9 (SWAP-9) Study
The purpose of this study is to compare the pharmacodynamic effects of ABCD-GENE guided vs. unguided de-escalation strategies among patients on dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI).
- Trial name
- SWAP-9 (NCT06588595)
- Testing
- Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel, Aspirin plus clopidogrel
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Florida
Coronary Artery Disease
Drug-Coated Balloon in Anticoagulated and Bleeding Risk Patients Undergoing PCI
The purpose of this study is to compare DCB with DES in stable CAD or ACS patients who are at high risk of bleeding. The hypothesis of the DEBATE trial is that the strategy using DCB and a shorter DAPT regimen is non-inferior to…
- Trial name
- DEBATE (NCT04814212)
- Testing
- Percutaneous coronary intervention using drug-coated balloon, Percutaneous coronary intervention using drug-eluting stent
- Where
- 14 sites in Finland, France and 2 more
- Volunteers
- 546 people
- Sponsor
- North Karelia Central Hospital
Coronary Artery Diseases
BIOFLOW III Satellite-Italy Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). 500 subjects will be enrolled in this registry.
- Trial name
- NCT02028728
- Where
- 18 sites in Italy
- Volunteers
- 609 people
- Sponsor
- Biotronik Italia S.p.A.
Chronic Total Occlusions of Coronary Arteries
Randomized Comparison of Optimal Medical Therapy and Percutaneous Recanalization for Chronic Total Occlusion (COMET-CTO)
Several meta analysis comparing successful Percutaneous Coronary Intervention of Chronic Total Occlusion (PCI-CTO) with unsuccessful PCI-CTO showed that there is significant reduction in short-term and long-term mortality.
- Trial name
- NCT02964975
- Testing
- Percutaneous coronary intervention, Optimal medical therapy
- Where
- Serbia
- Volunteers
- 100 people
- Sponsor
- Clinical Centre of Serbia
Acute Coronary Syndromes, Percutaneous Coronary Intervention
Effects of Intensive Antiplatelet Therapy for Patients With Clopidogrel Resistance After Coronary Stent Implantation
Clopidogrel resistance (CR) or low-responsiveness is associated with increased risk of ischemic events and can be detected by laboratory tests.
- Conditions
- Acute Coronary Syndromes, Percutaneous Coronary Intervention, Clopidogrel Low Responsiveness
- Trial name
- NCT01094457
- Testing
- aspirin, clopidogrel, aspirin, clopidogrel, cilostazol
- Where
- 3 sites in China
- Volunteers
- 840 people
- Sponsor
- Shenyang Northern Hospital
Chronic Renal Failure
Effect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure
This study is to evaluate the efficacy of sodium bicarbonate plus N-acetylcysteine for the prevention of contrast-induced nephropathy.
- Trial name
- NCT00716001
- Testing
- N-acetylcysteine
- Sponsor
- Osaka General Medical Center
Cardiovascular Diseases
Effect of Trimetazidine During the Primary PCI on Cardiac Function in Patients With ST-elevation Myocardial Infarction
Giving preoperative loading dose of 60mg of trimetazidine can safely and effectively reduce the PCI-related myocardial damage for the patients undergoing selective PCI.
- Trial name
- NCT02826616
- Testing
- Trimetazidine
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Chinese PLA General Hospital
Myocardial Infarction
Effect of Diabetes and Hepatic Enzymes Mutation on Clopidogrel VS Ticagrelor Activity in Myocardial Infarction (MI) Patients Undergoing Primary Percutaneous Coronary Intervention (PCI)
In this study the combined effect of diabetes mellitus and cyp2c19 polymorphism on platelet aggregation inhibitory activity of the highest traditionally used loading dose 600 mg clopidogrel and ticagrelor 180 mg loading dose will…
- Trial name
- NCT03613857
- Testing
- Clopidogrel, Ticagrelor 90mg
- Where
- Egypt
- Volunteers
- 1,022 people
- Sponsor
- Cairo University
Coronary Artery Disease, Acute Coronary Syndrome
Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI
Cangrelor is an intravenous P2Y12 inhibitor utilized as a bridge to achieve adequate platelet inhibition until oral P2Y12 inhibitors achieve their full antiplatelet effects in patients undergoing coronary stenting.
- Trial name
- SWAP-6 (NCT04668144)
- Testing
- Cangrelor, Prasugrel
- Where
- United States
- Volunteers
- 359 people
- Sponsor
- University of Florida
Aortic Stenosis, Multi Vessel Coronary Artery Disease
The TransCatheter Valve and Vessels Trial
The trial objective is to investigate whether Fractional Flow Reserve (FFR)-Guided Percutaneous Coronary Intervention (PCI) and TransCatheter Aortic Valve Implantation (TAVI) strategy for treatment of multivessel disease and…
- Conditions
- Aortic Stenosis, Multi Vessel Coronary Artery Disease, TAVI, CABG
- Trial name
- TCW (NCT03424941)
- Testing
- FFR-guided PCI and TAVI, CABG and SAVR
- Where
- 20 sites in Austria, Denmark and 8 more
- Volunteers
- 172 people
- Sponsor
- Maatschap Cardiologie Zwolle